Thalidomide has a significant effect in patients with thalassemia intermedia
Thalidomide has a significant effect in patients with thalassemia intermedia
复制标题
DOI：
10.1080/10245332.2017.1354427
复制
发表时间：
2018-01-01
期刊：
影响因子：
1.9
通讯作者：
Yin, Xiaolin
中科院分区：
文献类型：
--
作者：
Li, YunShuan;Ren, Quan;Yin, Xiaolin
目的：为探讨沙利度胺治疗中间型地中海贫血的疗效，对7例需要输血的中间型地中海贫血患者进行沙利度胺治疗观察。结果：4例输血不依赖患者中，3例血红蛋白浓度显著升高（>= 2 g/dl），1例血红蛋白浓度中度升高（1-2 g/dl）。治疗3个月后，与治疗前相比，血红蛋白浓度增加了3.2 +/- 1.2 g/dl。3例输血依赖患者中，1例治疗1个月后终止输血，另2例下降> 50%，并伴有平均血红蛋白浓度升高。结论：沙利度胺治疗中间型地中海贫血疗效显著。更大规模和更严格的设计的进一步研究是必要的。
Objective: To investigate the effect of thalidomide in patients with thalassemia intermedia.Methods: We observed the effect of thalidomide in seven patients with thalassemia intermedia requiring blood transfusion. Four of the patients were transfusion-independent, and three patients were transfusion-dependent.Results: For the four transfusion-independent patients, hemoglobin concentration increased significantly (>= 2 g/dl) in three and moderately ( 1-2 g/dl) in one. After 3 months of treatment, hemoglobin concentration increased 3.2 +/- 1.2 g/dl compared to pretreatment. Among the three transfusion-dependent patients, transfusion was terminated after one month of treatment in one patient and decreased > 50% in the other two patients, accompanied by an increase in the average hemoglobin concentration.Conclusion: Thalidomide had a significant effect in patients with thalassemia intermedia. Further studies of a larger scale and more rigorous design are warranted.